Viking Therapeutics (VKTX) Corporate presentation summary

Strategic focus and pipeline

• Focused on developing novel therapeutics for metabolic and endocrine diseases, with multiple clinical programs showing strong efficacy data.

• Lead asset VK2735, a GLP-1/GIP dual agonist, is being developed in both injectable and oral forms for obesity, with Phase 3 and Phase 2 studies underway or completed.

• Additional programs include an amylin agonist for obesity (IND planned 1Q26), VK2809 for MASH (successful Phase 2b), and VK0214 for X-ALD (successful Phase 1b).

VK2735 clinical results and efficacy

• VK2735 demonstrated up to 14.7% mean weight loss after 13 weeks in Phase 2 subcutaneous studies, with dose-dependent effects and no plateau observed.

• Oral VK2735 achieved up to 12.2% mean weight loss after 13 weeks, with progressive and durable effects maintained post-dosing.

• Both formulations showed rapid, progressive weight loss, with significant differences from placebo at all time points for doses above 15 mg.

• Exploratory maintenance cohorts suggest lower maintenance doses can sustain or extend weight loss.

Safety and tolerability

• Majority of treatment-emergent adverse events (TEAEs) were mild to moderate, with GI-related events (nausea, vomiting, diarrhea, constipation) most common and generally subsiding over time.

• Discontinuation rates were dose-dependent and mainly related to GI side effects, but most events resolved with titration.

• Promising tolerability profile observed through high dose levels in both oral and injectable studies.